Has a "Chemical Magic" Opened up New Prospects for Glaucoma?

Chemical modification of the prototype CB1R ago-PAM, GAT211, yielded new CB1R allosteric modulators (-)-(S,R)-13 and (+)-(R,S)-14, which showed significant bias for CB1R signaling pathways, as supported by docking studies. Compound 14 efficiently lowered elevated intraocular pressure when it is due to an increase in endocannabinoid tone. This article may open new avenues to meet the therapeutic needs presented by glaucoma.